AbbVie Inc logo

AbbVie Inc ABBV

Market Closed
14 Jun, 20:00
NYSE NYSE
$
168. 59
+2.03
+1.22%
After Hours
$
169. 42
+0.83 +0.49%
294.12B Market Cap
42.2 P/E Ratio
6.2% Div Yield
4,243,400 Volume
10.28 Eps
$ 166.56
Previous Close
Day Range
166 169.24
Year Range
130.96 182.89

ABBV Chart

AbbVie Inc Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. Richard A. Gonzalez CEO
NYSE Exchange
US00287Y1091 ISIN
US Country
50,000 Employees
15 May 2024 Last Dividend
- Last Split
2 Jan 2013 IPO Date

Overview

AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.

Products and Services

  • Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
  • Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
  • Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
  • Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
  • Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
  • Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
  • Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
  • Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
  • Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
  • Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
  • Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
  • Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
  • Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
  • Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
  • Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
  • Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
  • Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
  • Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
  • Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.

Contact Information

Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
Phone: 847 932 7900